Emtricitabine, rilpivirine, and tenofovir and Lasmiditan
Determining the interaction of Emtricitabine, rilpivirine, and tenofovir and Lasmiditan and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan. The clinical relevance is unknown. MANAGEMENT: Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary. References "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.
Professional:GENERALLY AVOID: Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan. The clinical relevance is unknown.
MANAGEMENT: Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.
- "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.
Generic Name: emtricitabine / rilpivirine / tenofovir
Brand name: Complera, Odefsey
Synonyms: Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Emtricitabine, rilpivirine, and tenofovir-Latanoprost
- Emtricitabine, rilpivirine, and tenofovir-Latanoprost and netarsudil ophthalmic
- Emtricitabine, rilpivirine, and tenofovir-Latanoprost and Timolol
- Emtricitabine, rilpivirine, and tenofovir-Latanoprost Eye Drops (Emulsion)
- Emtricitabine, rilpivirine, and tenofovir-Latanoprost Eye Drops (Solution)
- Emtricitabine, rilpivirine, and tenofovir-Latanoprost ophthalmic
- Lasmiditan-Emtricitabine, Rilpivirine, and Tenofovir Alafenamide
- Lasmiditan-Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate
- Lasmiditan-Emtriva
- Lasmiditan-Emtriva (Emtricitabine Capsules)
- Lasmiditan-Emtriva (Emtricitabine Solution)
- Lasmiditan-Emverm